| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 |
| Sales | 190 | 650 | 200 | 110 | 230 |
| Sales Growth | -70.77% | +225.00% | +81.82% | -52.17% | -30.30% |
| Net Income | -3,540 | -4,480 | -5,740 | -4,760 | -4,410 |
| Net Income Growth | +20.98% | +21.95% | -20.59% | -7.94% | +12.15% |
Tff Pharmaceuticals Inc (TFFP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
TFF Pharmaceuticals Inc. is an early-stage biopharmaceutical company. It is focused on the development and commercialization of inhalation products for the treatment of chronic respiratory diseases and lung conditions. TFF Pharmaceuticals Inc. is based in Austin, Texas.
Fiscal Year End Date: 12/31